Naproxcinod Effective But Safety Concerns Remain, Advisory Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Members overwhelmingly vote against recommending approval for the novel NSAID, a combination of naproxen and nitric oxide.
You may also be interested in...
Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.
Naproxcinod Must Show More Data On Both Safety And Therapeutic Benefit After "Complete Response" Letter
FDA tells NicOx it wants long-term studies on drug's cardiovascular and gastrointestinal safety, but no additional efficacy trials.
A Painstaking Approach: Can Anti-NGFs Give Relief To Pharma Pipeline Woes?
Analgesic drugs have reached a painful point. Unwanted side effects and abuse potential have made existing drug categories such as non-steroidal anti-inflammatories and opioids unappealing prescriptions for patients in chronic pain. But a new class of antibodies that inhibit the crucial protein nerve growth factor could spell relief for millions of chronic pain sufferers - if they can demonstrate safety and efficacy